{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:16:00Z","timestamp":1782980160448,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gastrointestinal endoscopy has been associated with difficult experiences and can leave patients with an unpleasant impression. Propofol and midazolam are the most commonly used intravenous anesthetics for sedation during gastrointestinal endoscopy. However, cardiac and pulmonary adverse events are the primary concerns associated with the use of these sedatives. Remimazolam tosylate is an ultra-short-acting benzodiazepine drug with a mild inhibitory effect on the respiratory and circulatory systems. These properties qualify remimazolam tosylate to be used as a replacement for propofol or midazolam as a sedative during gastrointestinal endoscopy. This study aims to describe the efficacy and safety of remimazolam tosylate as a sedative for upper gastrointestinal endoscopy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A multicenter, randomized, single-blind, parallel-controlled, noninferiority clinical study will be conducted to evaluate the efficacy and safety of remimazolam tosylate as a sedative during upper gastrointestinal endoscopy. Participants (<jats:italic>n<\/jats:italic> = 1800) will be randomized to receive remimazolam tosylate at 0.15 mg\/kg (experimental group 1), remimazolam tosylate at 0.2 mg\/kg (experimental group 2), or propofol at 1.5 mg\/kg (control group). Procedure success will be assessed and defined as the completion of upper gastrointestinal endoscopy without the administration of a rescue sedative agent or more than two top-up doses of the trial drug in any 5-min period after initial administration. Sedation quality will be evaluated using the Modified Observer\u2019s Assessment of Alertness\/Sedation score. Adverse events will be recorded to evaluate safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study will determine the optimal dosage of remimazolam tosylate during upper gastrointestinal endoscopy and will describe its efficacy and safety. These findings may contribute to a more comfortable and safer experience for patients compared with that when the conventional sedative propofol is used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> NCT04727034. Registered on February 18, 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06935-0","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:08:56Z","timestamp":1670821736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of remimazolam tosylate for sedation during upper gastrointestinal endoscopy: study protocol for a multicenter randomized controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Huichen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxue","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Huai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9755-1025","authenticated-orcid":false,"given":"Diansan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"issue":"4","key":"6935_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.4103\/1658-354X.140893","volume":"8","author":"BG Goudra","year":"2014","unstructured":"Goudra BG, Singh PM. Propofol alternatives in gastrointestinal endoscopy anesthesia. Saudi J Anaesth. 2014;8(4):540\u20135.","journal-title":"Saudi J Anaesth"},{"issue":"11","key":"6935_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.dld.2017.08.038","volume":"49","author":"R Conigliaro","year":"2017","unstructured":"Conigliaro R, Fanti L, Manno M, Brosolo P, Italian Society of Digestive Endoscopy (SIED) Sedation Group. Italian Society of Digestive Endoscopy (SIED) position paper on the non-anaesthesiologist administration of propofol for gastrointestinal endoscopy. Dig Liver Dis. 2017;49(11):1185\u201390.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"6935_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/2050640618767594","volume":"6","author":"T Nishizawa","year":"2018","unstructured":"Nishizawa T, Suzuki H. Propofol for gastrointestinal endoscopy. United Eur Gastroenterol J. 2018;6(6):801\u20135.","journal-title":"United Eur Gastroenterol J"},{"key":"6935_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.emc.2004.12.016","volume":"23","author":"MA Miller","year":"2005","unstructured":"Miller MA, Levy P, Patel MM. Procedural sedation and analgesia in the emergency department: what are the risks? Emerg Med Clin North Am. 2005;23:551\u201372.","journal-title":"Emerg Med Clin North Am"},{"issue":"5","key":"6935_CR5","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/j.1572-0241.2006.00500.x","volume":"101","author":"LB Cohen","year":"2006","unstructured":"Cohen LB, Wecsler JS, Gaetano JN, Benson AA, Miller KM, Durkalski V, et al. Endoscopic sedation in the United States: results from a nationwide survey. Am J Gastroenterol. 2006;101(5):967\u201374.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"6935_CR6","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1038\/s41598-017-03154-5","volume":"7","author":"M Balk","year":"2017","unstructured":"Balk M, Hentschke H, Rudolph U, Antkowiak B, Drexler B. Differential depression of neuronal network activity by midazolam and its main metabolite 1-hydroxymidazolam in cultured neocortical slices. Sci Rep. 2017;7(1):3503.","journal-title":"Sci Rep"},{"key":"6935_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1213\/ANE.0b013e31823acb95","volume":"115","author":"JR Sneyd","year":"2012","unstructured":"Sneyd JR. Remimazolam: new beginnings or just a me-too? Anesth Analg. 2012;115:217\u20139.","journal-title":"Anesth Analg"},{"issue":"3","key":"6935_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0736-4679(97)00022-X","volume":"15","author":"SP Nordt","year":"1997","unstructured":"Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med. 1997;15(3):357\u201365.","journal-title":"J Emerg Med"},{"issue":"4","key":"6935_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/ACO.0000000000000877","volume":"33","author":"JR Sneyd","year":"2020","unstructured":"Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol. 2020;33(4):506\u201311.","journal-title":"Curr Opin Anaesthesiol"},{"key":"6935_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/01.anes.0000267503.85085.c0","volume":"107","author":"GJ Kilpatrick","year":"2007","unstructured":"Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology. 2007;107:60\u20136.","journal-title":"Anesthesiology"},{"issue":"12","key":"6935_CR11","first-page":"929","volume":"13","author":"WK Rogers","year":"2010","unstructured":"Rogers WK, McDowell TS. Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and\/or anesthesia in day-case surgical and non-surgical procedures. IDrugs. 2010;13(12):929\u201337.","journal-title":"IDrugs."},{"issue":"1","key":"6935_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/cbdd.12731","volume":"88","author":"Y Liu","year":"2016","unstructured":"Liu Y, Xu X, Xie J, Ma H, Wang T, Zhang G, et al. Design, synthesis, and biological evaluation of novel CNS 7056 derivatives as sedatives in rats and rabbits. Chem Biol Drug Des. 2016;88(1):38\u201342.","journal-title":"Chem Biol Drug Des"},{"issue":"5","key":"6935_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.gie.2015.08.062","volume":"83","author":"DJ Pambianco","year":"2016","unstructured":"Pambianco DJ, Borkett KM, Riff DS, Winkle PJ, Schwartz HI, Melson TI, et al. A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2016;83(5):984\u201392.","journal-title":"Gastrointest Endosc"},{"issue":"2","key":"6935_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1213\/ANE.0b013e31823f0c28","volume":"115","author":"LJ Antonik","year":"2012","unstructured":"Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012;115(2):274\u201383.","journal-title":"Anesth Analg"},{"issue":"3","key":"6935_CR15","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1097\/MCG.0000000000001630","volume":"56","author":"H Fatima","year":"2022","unstructured":"Fatima H, Imperiale T. Safety profile of endoscopist-directed balanced propofol sedation for procedural sedation: an experience at a hospital-based endoscopy unit. J Clin Gastroenterol. 2022;56(3):e209\u201315.","journal-title":"J Clin Gastroenterol"},{"key":"6935_CR16","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.2147\/DDDT.S339535","volume":"15","author":"X Liu","year":"2021","unstructured":"Liu X, Ding B, Shi F, Zhang Y, Liu L, Sha Y, et al. The efficacy and safety of remimazolam tosilate versus etomidate-propofol in elderly outpatients undergoing colonoscopy: a prospective, randomized, single-blind, non-inferiority trial. Drug Des Devel Ther. 2021;15:4675\u201385.","journal-title":"Drug Des Devel Ther"},{"key":"6935_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3389\/fphar.2019.00251","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Hu P, Huang Y, Sang N, Song K, Wang H, et al. Corrigendum: population pharmacokinetic\/pharmacodynamic model-guided dosing optimization of a novel sedative HR7056 in Chinese Healthy Subjects. Front Pharmacol. 2019;10:251.","journal-title":"Front Pharmacol"},{"issue":"1","key":"6935_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bja.2021.03.028","volume":"127","author":"JR Sneyd","year":"2021","unstructured":"Sneyd JR, Gambus PL, Rigby-Jones AE. Current status of perioperative hypnotics, role of benzodiazepines, and the case for remimazolam: a narrative review. Br J Anaesth. 2021;127(1):41\u201355.","journal-title":"Br J Anaesth"},{"issue":"1","key":"6935_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/bja\/aer407","volume":"108","author":"KP Mason","year":"2012","unstructured":"Mason KP, Green SM, Piacevoli Q, International Sedation Task Force. Adverse event reporting tool to standardize the reporting and tracking of adverse events during procedural sedation: a consensus document from the World SIVA International Sedation Task Force. Br J Anaesth. 2012;108(1):13\u201320.","journal-title":"Br J Anaesth"},{"issue":"2","key":"6935_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.bja.2018.04.027","volume":"121","author":"HR Zheng","year":"2018","unstructured":"Zheng HR, Zhang XQ, Li LZ, Wang YL, Wei Y, Chen YM, et al. Multicentre prospective cohort study evaluating gastroscopy without sedation in China. Br J Anaesth. 2018;121(2):508\u201311.","journal-title":"Br J Anaesth"},{"issue":"1","key":"6935_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bja.2021.01.028","volume":"127","author":"S Zhou","year":"2021","unstructured":"Zhou S, Zhu Z, Dai W, Qi S, Tian W, Zhang Y, et al. National survey on sedation for gastrointestinal endoscopy in 2758 Chinese hospitals. Br J Anaesth. 2021;127(1):56\u201364.","journal-title":"Br J Anaesth"},{"issue":"3","key":"6935_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.giec.2016.03.002","volume":"26","author":"GS Kochhar","year":"2016","unstructured":"Kochhar GS, Gill A, Vargo JJ. On the horizon: the future of procedural sedation. Gastrointest Endosc Clin N Am. 2016;26(3):577\u201392.","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"3","key":"6935_CR23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/bja\/aeq190","volume":"105","author":"JR Sneyd","year":"2010","unstructured":"Sneyd JR, Rigby-Jones AE. New drugs and technologies, intravenous anaesthesia is on the move (again). Br J Anaesth. 2010;105(3):246\u201354.","journal-title":"Br J Anaesth"},{"issue":"4","key":"6935_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/ACO.0000000000000202","volume":"28","author":"TG Hansen","year":"2015","unstructured":"Hansen TG. Sedative medications outside the operating room and the pharmacology of sedatives. Curr Opin Anaesthesiol. 2015;28(4):446\u201352.","journal-title":"Curr Opin Anaesthesiol"},{"issue":"2","key":"6935_CR25","first-page":"1067","volume":"289","author":"B Tuk","year":"1999","unstructured":"Tuk B, van Oostenbruggen MF, Herben VM, Mandema JW, Danhof M. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J Pharmacol Exp Ther. 1999;289(2):1067\u201374.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"6935_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/bjp.2008.228","volume":"155","author":"R Upton","year":"2008","unstructured":"Upton R, Martinez A, Grant C. A dose escalation study in sheep of the effects of the benzodiazepine CNS 7056 on sedation, the EEG and the respiratory and cardiovascular systems. Br J Pharmacol. 2008;155(1):52\u201361.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"6935_CR27","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.anclin.2017.01.017","volume":"35","author":"MK Tanious","year":"2017","unstructured":"Tanious MK, Beutler SS, Kaye AD, Urman RD. New hypnotic drug development and pharmacologic considerations for clinical anesthesia. Anesthesiol Clin. 2017;35(2):e95\u2013e113.","journal-title":"Anesthesiol Clin"},{"issue":"2","key":"6935_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/ALN.0b013e3181ae8460","volume":"111","author":"TD Egan","year":"2009","unstructured":"Egan TD. Is anesthesiology going soft?: trends in fragile pharmacology. Anesthesiology. 2009;111(2):229\u201330.","journal-title":"Anesthesiology."},{"issue":"9","key":"6935_CR29","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/phar.1806","volume":"36","author":"AM Wesolowski","year":"2016","unstructured":"Wesolowski AM, Zaccagnino MP, Malapero RJ, Kaye AD, Urman RD. Remimazolam: pharmacologic considerations and clinical role in anesthesiology. Pharmacotherapy. 2016;36(9):1021\u20137.","journal-title":"Pharmacotherapy."},{"issue":"6","key":"6935_CR30","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/bja\/aep269","volume":"103","author":"RN Upton","year":"2009","unstructured":"Upton RN, Martinez AM, Grant C. Comparison of the sedative properties of CNS 7056, midazolam, and propofol in sheep. Br J Anaesth. 2009;103(6):848\u201357.","journal-title":"Br J Anaesth"},{"issue":"4","key":"6935_CR31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/ACO.0000000000000614","volume":"31","author":"JW Sear","year":"2018","unstructured":"Sear JW. Challenges of bringing a new sedative to market! Curr Opin Anaesthesiol. 2018;31(4):423\u201330.","journal-title":"Curr Opin Anaesthesiol"},{"issue":"4","key":"6935_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00540-020-02755-1","volume":"34","author":"K Masui","year":"2020","unstructured":"Masui K. Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!! J Anesth. 2020;34(4):479\u201382.","journal-title":"J Anesth"},{"issue":"3","key":"6935_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00228-019-02800-3","volume":"76","author":"XY Sheng","year":"2020","unstructured":"Sheng XY, Liang Y, Yang XY, Li LE, Ye X, Zhao X, et al. Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers. Eur J Clin Pharmacol. 2020;76(3):383\u201391.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"6935_CR34","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ALN.0000000000003103","volume":"132","author":"J Sch\u00fcttler","year":"2020","unstructured":"Sch\u00fcttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: Part I. Pharmacokinetics and Clinical Pharmacodynamics. Anesthesiology. 2020;132(4):636\u201351.","journal-title":"Anesthesiology"},{"issue":"3","key":"6935_CR35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.4103\/1658-354X.136627","volume":"8","author":"BG Goudra","year":"2014","unstructured":"Goudra BG, Singh PM. Remimazolam: the future of its sedative potential. Saudi J Anaesth. 2014;8(3):388\u201391.","journal-title":"Saudi J Anaesth"},{"issue":"10","key":"6935_CR36","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1007\/s10620-020-06044-5","volume":"65","author":"B Goudra","year":"2020","unstructured":"Goudra B, Gouda G, Mohinder P. Recent developments in drugs for GI endoscopy sedation. Dig Dis Sci. 2020;65(10):2781\u20138.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"6935_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00540-020-02788-6","volume":"34","author":"M Doi","year":"2020","unstructured":"Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efcacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb\/III trial. J Anesth. 2020;34(4):543\u201353.","journal-title":"J Anesth"},{"issue":"1","key":"6935_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.chest.2018.09.015","volume":"155","author":"NJ Pastis","year":"2019","unstructured":"Pastis NJ, Yarmus LB, Schippers F, Ostroff R, Chen A, Akulian J, et al. Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest. 2019;155(1):137\u201346.","journal-title":"Chest."},{"issue":"5","key":"6935_CR39","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1213\/ANE.0b013e3182a705ae","volume":"117","author":"MT Worthington","year":"2013","unstructured":"Worthington MT, Antonik LJ, Goldwater DR, Lees JP, Wilhelm-Ogunbiyi K, Borkett KM, et al. A phase Ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesth Analg. 2013;117(5):1093\u2013100.","journal-title":"Anesth Analg"},{"issue":"4","key":"6935_CR40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1213\/ANE.0000000000000548","volume":"120","author":"KM Borkett","year":"2015","unstructured":"Borkett KM, Riff DS, Schwartz HI, Winkle PJ, Pambianco DJ, Lees JP, et al. A Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth Analg. 2015;120(4):771\u201380.","journal-title":"Anesth Analg"},{"issue":"3","key":"6935_CR41","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.gie.2018.04.2351","volume":"88","author":"DK Rex","year":"2018","unstructured":"Rex DK, Bhandari R, Desta T, DeMicco MP, Schaeffer C, Etzkorn K, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2018;88(3):427\u2013437.e6.","journal-title":"Gastrointest Endosc"},{"issue":"4","key":"6935_CR42","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.clinthera.2020.02.006","volume":"42","author":"X Chen","year":"2020","unstructured":"Chen X, Sang N, Song K, Zhong W, Wang H, Jiang J, et al. Psychomotor recovery following remimazolam-induced sedation and the effectiveness of flumazenil as an antidote. Clin Ther. 2020;42(4):614\u201324.","journal-title":"Clin Ther"},{"issue":"2","key":"6935_CR43","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/jgh.15188","volume":"36","author":"SH Chen","year":"2021","unstructured":"Chen SH, Yuan TM, Zhang J, Bai H, Tian M, Pan CX, et al. Remimazolam tosilate in upper gastrointestinal endoscopy: a multicenter, randomized, non-inferiority, phase III trial. J Gastroenterol Hepatol. 2021;36(2):474\u201381.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"6935_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12871-020-01049-z","volume":"20","author":"M Chen","year":"2020","unstructured":"Chen M, Lu Y, Liu H, Fu Q, Li J, Wu J, et al. The propofol-sparing effect of intravenous lidocaine in elderly patients undergoing colonoscopy: a randomized, double-blinded, controlled study. BMC Anesthesiol. 2020;20(1):132.","journal-title":"BMC Anesthesiol"},{"issue":"1","key":"6935_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12871-017-0341-3","volume":"17","author":"M Lei","year":"2017","unstructured":"Lei M, Zhang P, Liu Y, Fu F, Ye L, Zhu T. Propofol and sufentanil may affect the patients\u2019 sleep quality independently of the surgical stress response: a prospective nonrandomized controlled trial in 1033 patients\u2019 undergone diagnostic upper gastrointestinal endoscopy. BMC Anesthesiol. 2017;17(1):53.","journal-title":"BMC Anesthesiol"},{"issue":"3","key":"6935_CR46","first-page":"393","volume":"88","author":"S Chokhavatia","year":"1993","unstructured":"Chokhavatia S, Nguyen L, Williams R, Kao J, Heavner JE. Sedation and analgesia for gastrointestinal endoscopy. Am J Gastroenterol. 1993;88(3):393\u20136.","journal-title":"Am J Gastroenterol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06935-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06935-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06935-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:15:58Z","timestamp":1670822158000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06935-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6935"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06935-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]},"assertion":[{"value":"11 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical trial has been approved and supported by the ethics committee of the Renji Hospital Shanghai Jiaotong University School of Medicine (KY2020-127).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"995"}}